文献速递消化系统肿瘤

CONKO-005:吉西他滨联合厄洛替尼对比吉西他滨单药用于胰腺癌R0切除术后辅助化疗的多中心随机III期试验

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2017-08-17

CONKO-005研究在57个中心随机入组436例R0切除的胰腺导管腺癌患者,比较吉西他滨联合厄洛替尼(GemErlo)与吉西他滨(Gem)单药辅助化疗6周期的疗效。中位随访54个月,两组中位无病生存期均为11.4个月,中位总生存期分别为24.5个月和26.5个月,联合厄洛替尼未改善DFS或OS。

要点

  • GemErlo组与Gem组中位DFS均为11.4个月,无差异。
  • GemErlo组中位OS 24.5个月 vs Gem组26.5个月,无差异。
  • GemErlo组5年生存率25% vs Gem组20%,仅为趋势。

核心结论

  • 在R0切除的胰腺导管腺癌患者中,吉西他滨联合厄洛替尼24周对比吉西他滨单药未改善无病生存期或总生存期。

研究设计与样本

  • 开放标签、多中心随机III期试验,2008年4月至2013年7月间在57个研究中心随机入组436例R0切除的胰腺导管腺癌患者。
  • 患者随机分配至吉西他滨1000 mg/m2第1、8、15天每4周重复联合厄洛替尼100 mg每日一次(GemErlo)或吉西他滨单药(Gem),共6周期。

主要发现

  • 中位随访54个月,共观察到361例(83%)疾病复发。
  • 两组中位治疗时间均为22周;中位无病生存期GemErlo组11.4个月 vs Gem组11.4个月。
  • 中位总生存期GemErlo组24.5个月 vs Gem组26.5个月。
  • 1年、2年和5年估计生存率GemErlo组分别为77%、53%和25%,Gem组分别为79%、54%和20%,呈GemErlo长期生存趋势。
  • GemErlo组中皮疹的发生或分级与更好的生存无关。

关键数值与推荐

  • 主要终点为联合厄洛替尼将无病生存期从14个月提高至18个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo) or gemcitabine (Gem) alone for six cycles. The primary end point of the study was to improve disease-free survival (DFS) from 14 to 18 months by adding erlotinib to gemcitabine. Results In all, 436 patients were randomly assigned at 57 study centers between April 2008 and July 2013. A total of 361 instances (83%) of disease recurrence were observed after a median follow-up of 54 months. Median treatment duration was 22 weeks in both arms. There was no difference in median DFS (GemErlo 11.4 months; Gem 11.4 months) or median overall survival (GemErlo 24.5 months; Gem 26.5 months). There was a trend toward long-term survival in favor of GemErlo (estimated survival after 1, 2, and 5 years for GemErlo was 77%, 53%, and 25% v 79%, 54%, and 20% for Gem, respectively). The occurrence or the grade of rash was not associated with a better survival in the GemErlo arm. Conclusion To the best of our knowledge, CONKO-005 is the first study to investigate the combination of chemotherapy and a targeted therapy in the adjuvant treatment of PDAC. GemErlo for 24 weeks did not improve DFS or overall survival over Gem.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sinn M, Bahra M, Liersch T, et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J Clin Oncol. 2017. PMID: 28817370. doi:10.1200/JCO.2017.72.6463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。